GEN-MKT-18-7897-A
Jan 13, 2025 | Blogs, Pharma, ZenoTOF 7600 system | 0 comments
Read time: 2 minutes
It is no secret that (bio)pharmaceutical research and development is complex, both scientific and regulatory processes. Working for a contract research organization and more recently for SCIEX has provided an interesting perspective on trends the market experiences that affect many of us.
Outsourcing
It has been my experience that advancements in technology, particularly in mass spectrometry, have significantly transformed the capabilities and roles of Contract Development and Manufacturing Organizations (CDMOs) and Contract Research Organizations (CROs) in the drug development life cycle. High-resolution mass spectrometry (HRMS) has revolutionized the characterization of complex molecules, enabling precise identification of potential drug candidates and a deeper understanding of their mechanisms of action. Techniques like tandem mass spectrometry (MS/MS) and advanced fragmentation methods such as Electron-Activated Dissociation (EAD) from SCIEX allow for detailed structural elucidation and quantitation of biomolecules, facilitating the development of more targeted and effective therapies.
Artificial intelligence and machine learning
Integrating artificial intelligence (AI) and machine learning (ML) algorithms with mass spectrometry data enhances the potential of CDMOs and CROs by providing predictive insights and optimization strategies for drug discovery and manufacturing processes, improving efficiency and decision-making.
Advanced techniques like native mass spectrometry allow the study of biomolecules in their natural state, aiding research on protein complexes and interactions critical for biologics and personalized medicine. As technology continues to evolve, mass spectrometry will further enhance the efficiency, accuracy, and scope of services offered by CDMOs and CROs, driving innovation in drug development, and leading to the discovery of novel new medicines.
Biosecure Act
Looking forward I expect, the Biosecure Act will undoubtedly complicate biopharmaceutical business, especially in Asia, and this shift is likely to reshape the global biotech landscape. U.S. firms will face more hurdles during collaborations, particularly around gene-editing and sensitive pathogen research. Tightening biosecurity regulations may cause U.S. companies to seek research partners and suppliers based in regions that align better with these new standards, meaning new places may be seen as attractive hubs for innovation, partnerships, and investments. I expect we’ll see a more diversified global distribution of biotech work.
For more information about how SCIEX can support you please visit our website, here>
It is no secret that (bio)pharmaceutical research and development is complex, both scientific and regulatory processes. Here is an overview of just some of the ways SCIEX is working to support these challenges.
In a recent webinar, available on demand, scientists Luiza Chrojan and Ryan Hylands from Pharmaron, provided insights into the deployment of capillary gel electrophoresis (CGE) within cell and gene therapy. Luiza and Ryan shared purity data on plasmids used for adeno-associated virus (AAV) manufacturing and data on AAV genome integrity, viral protein (VP) purity and VP ratios using the BioPhase 8800 system.
Last year, Technology Networks hosted two webinars that featured groundbreaking research utilizing SWATH DIA (data-independent acquisition) for exposomics and metabolomics. Researchers Dr. Vinicius Verri Hernandes from the University of Vienna and Dr. Cristina Balcells from Imperial College London (ICL) demonstrated how a DIA approach can be successfully implemented in small molecule analysis using the ZenoTOF 7600 system. Their innovative approaches highlight the potential of SWATH DIA to enhance the detection and analysis of chemical exposures and metabolites, paving the way for new insights into environmental health and disease mechanisms.
Posted by
You must be logged in to post a comment.
Share this post with your network